News

Creo Medical’s flotation awarded

Deal of the Year at the 2017 Insider Wales Dealmakers Awards

Read More

US FDA Approval of Speedboat RS2

Approval comes ahead of schedule; Company to implement commercial plans

Read More

Creo Medical Announces Participation in SUMCASTEC Research Programme

Multidisciplinary Consortium Awarded €4 Million Grant Programme Focused on Isolation and Neutralization of Cancer Stem Cells

Read More

Admission to AIM and First Day of Dealings

Chepstow, South Wales, 9 December 2016 – Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the admission from 8:00 am today of its ordinary shares to trading on AIM, a market operated by the London Stock Exchange plc ("Admission") and the commencement of dealings in its Ordinary Shares under the TIDM "CREO" and with ISIN number GB00BZ1BLL44.

Read More